Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Paik, E. Sun | - |
dc.contributor.author | Kim, Tae-Hyun | - |
dc.contributor.author | Cho, Young Jae | - |
dc.contributor.author | Ryu, Jiyoon | - |
dc.contributor.author | Choi, Jung-Joo | - |
dc.contributor.author | Lee, Yoo-Young | - |
dc.contributor.author | Kim, Tae-Joong | - |
dc.contributor.author | Choi, Chel-Hun | - |
dc.contributor.author | Kim, Woo Young | - |
dc.contributor.author | Sa, Jason K. | - |
dc.contributor.author | Lee, Jin-Ku | - |
dc.contributor.author | Kim, Byoung-Gie | - |
dc.contributor.author | Bae, Duk-Soo | - |
dc.contributor.author | Han, Hee Dong | - |
dc.contributor.author | Ahn, Hyung Jun | - |
dc.contributor.author | Lee, Jeong-Won | - |
dc.date.accessioned | 2021-08-31T06:23:49Z | - |
dc.date.available | 2021-08-31T06:23:49Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-03-17 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/57261 | - |
dc.description.abstract | Axitinib, small molecule tyrosine kinase inhibitor, demonstrates anti-cancer activity for various solid tumors. We investigated anti-cancer effect of axitinib in epithelial ovarian cancer (EOC). We treated EOC cells (A2780, HeyA8, RMG1, and HeyA8-MDR) with axitinib to evaluate its effects on cell viabilty, apoptosis and migration. Western blots were performed to assess VEGFR2, ERK, and AKT levels, and ELISA and FACS to evaluate apoptosis according to axitinib treatment. In addition, in vivo experiments in xenografts using A2780, RMG1, and HeyA8-MDR cell lines were performed. We repeated the experiment with patient-derived xenograft models (PDX) of EOC. Axitinib significantly inhibited cell survival and migration, and increased apoptosis in EOC cells. The expression of VEGFR2 and phosphorylation of AKT and ERK in A2780, RMG1, and HeyA8 were decreased with axitinib treatment in dose-dependent manner, but not in HeyA8-MDR. In in vivo experiments, axitinib significantly decreased tumor weight in xenograft models of drug-sensitive (A2780), and clear cell carcinoma (RMG1) and PDX models for platinum sensitive EOC compared to control, but was not effective in drug-resistant cell line (HeyA8-MDR) or heavily pretreated refractory PDX model. Axitinib showed significant anti-cancer effects in drug-sensitive or clear cell EOC cells via inhibition of VEGFR signals associated with cell proliferation, apoptosis and migration, but not in drug-resistant cells. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject | PHASE-II | - |
dc.subject | CELL | - |
dc.subject | RECEPTOR | - |
dc.subject | BEVACIZUMAB | - |
dc.subject | COMBINATION | - |
dc.subject | SORAFENIB | - |
dc.subject | CARCINOMA | - |
dc.subject | EFFICACY | - |
dc.subject | MODELS | - |
dc.title | Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Sa, Jason K. | - |
dc.identifier.doi | 10.1038/s41598-020-61871-w | - |
dc.identifier.scopusid | 2-s2.0-85082002887 | - |
dc.identifier.wosid | 000563450600010 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.10, no.1 | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | CELL | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | MODELS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.